Prometheus Biosciences, Inc. (RXDX) Stock Competitors & Peer Comparison
See (RXDX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RXDX | $199.92 | +0.09% | 9.6B | -56.47 | -$3.54 | N/A |
| VRTX | $468.34 | +3.70% | 118.5B | 27.70 | $16.85 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $617.19 | +1.19% | 63.1B | 14.96 | $40.94 | +0.60% |
| ARGX | $929.38 | +5.89% | 55.9B | 40.22 | $22.47 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $290.10 | +4.32% | 38.2B | 71.96 | $3.98 | N/A |
| RVMDW | $7.61 | +10.29% | 35.8B | N/A | N/A | N/A |
| RVMD | $170.49 | +4.60% | 35.3B | -23.32 | -$7.11 | N/A |
| MRNA | $62.27 | -2.64% | 23.5B | -7.29 | -$8.14 | N/A |
Stock Comparison
RXDX vs VRTX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, VRTX has a market cap of 118.5B. Regarding current trading prices, RXDX is priced at $199.92, while VRTX trades at $468.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas VRTX's P/E ratio is 27.70. In terms of profitability, RXDX's ROE is -0.31%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, RXDX is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check VRTX's competition here
RXDX vs VRNA Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, RXDX is priced at $199.92, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas VRNA's P/E ratio is -102.80. In terms of profitability, RXDX's ROE is -0.31%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, RXDX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check VRNA's competition here
RXDX vs REGN Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, REGN has a market cap of 63.1B. Regarding current trading prices, RXDX is priced at $199.92, while REGN trades at $617.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas REGN's P/E ratio is 14.96. In terms of profitability, RXDX's ROE is -0.31%, compared to REGN's ROE of +0.14%. Regarding short-term risk, RXDX is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check REGN's competition here
RXDX vs ARGX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ARGX has a market cap of 55.9B. Regarding current trading prices, RXDX is priced at $199.92, while ARGX trades at $929.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ARGX's P/E ratio is 40.22. In terms of profitability, RXDX's ROE is -0.31%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, RXDX is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ARGX's competition here
RXDX vs SGEN Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RXDX is priced at $199.92, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RXDX's ROE is -0.31%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RXDX is less volatile compared to SGEN. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check SGEN's competition here
RXDX vs ALNY Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ALNY has a market cap of 38.2B. Regarding current trading prices, RXDX is priced at $199.92, while ALNY trades at $290.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ALNY's P/E ratio is 71.96. In terms of profitability, RXDX's ROE is -0.31%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, RXDX is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ALNY's competition here
RXDX vs RVMDW Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, RVMDW has a market cap of 35.8B. Regarding current trading prices, RXDX is priced at $199.92, while RVMDW trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas RVMDW's P/E ratio is N/A. In terms of profitability, RXDX's ROE is -0.31%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, RXDX is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check RVMDW's competition here
RXDX vs RVMD Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, RVMD has a market cap of 35.3B. Regarding current trading prices, RXDX is priced at $199.92, while RVMD trades at $170.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas RVMD's P/E ratio is -23.32. In terms of profitability, RXDX's ROE is -0.31%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, RXDX is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check RVMD's competition here
RXDX vs MRNA Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, MRNA has a market cap of 23.5B. Regarding current trading prices, RXDX is priced at $199.92, while MRNA trades at $62.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas MRNA's P/E ratio is -7.29. In terms of profitability, RXDX's ROE is -0.31%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, RXDX is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check MRNA's competition here
RXDX vs RPRX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, RPRX has a market cap of 23B. Regarding current trading prices, RXDX is priced at $199.92, while RPRX trades at $54.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas RPRX's P/E ratio is 28.19. In terms of profitability, RXDX's ROE is -0.31%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, RXDX is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check RPRX's competition here
RXDX vs UTHR Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, UTHR has a market cap of 22.8B. Regarding current trading prices, RXDX is priced at $199.92, while UTHR trades at $545.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas UTHR's P/E ratio is 19.91. In terms of profitability, RXDX's ROE is -0.31%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RXDX is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check UTHR's competition here
RXDX vs BNTX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, BNTX has a market cap of 22.8B. Regarding current trading prices, RXDX is priced at $199.92, while BNTX trades at $91.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas BNTX's P/E ratio is -15.31. In terms of profitability, RXDX's ROE is -0.31%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, RXDX is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check BNTX's competition here
RXDX vs ROIV Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ROIV has a market cap of 22.5B. Regarding current trading prices, RXDX is priced at $199.92, while ROIV trades at $31.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ROIV's P/E ratio is -57.87. In terms of profitability, RXDX's ROE is -0.31%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, RXDX is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ROIV's competition here
RXDX vs INSM Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, INSM has a market cap of 20.8B. Regarding current trading prices, RXDX is priced at $199.92, while INSM trades at $102.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas INSM's P/E ratio is -16.63. In terms of profitability, RXDX's ROE is -0.31%, compared to INSM's ROE of -1.30%. Regarding short-term risk, RXDX is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check INSM's competition here
RXDX vs BGNE Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RXDX is priced at $199.92, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RXDX's ROE is -0.31%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, RXDX is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check BGNE's competition here
RXDX vs INCY Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, INCY has a market cap of 19.6B. Regarding current trading prices, RXDX is priced at $199.92, while INCY trades at $104.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas INCY's P/E ratio is 13.87. In terms of profitability, RXDX's ROE is -0.31%, compared to INCY's ROE of +0.29%. Regarding short-term risk, RXDX is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check INCY's competition here
RXDX vs DNA-WT Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RXDX is priced at $199.92, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RXDX's ROE is -0.31%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, RXDX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check DNA-WT's competition here
RXDX vs NBIX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, NBIX has a market cap of 16.3B. Regarding current trading prices, RXDX is priced at $199.92, while NBIX trades at $162.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas NBIX's P/E ratio is 24.83. In terms of profitability, RXDX's ROE is -0.31%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, RXDX is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check NBIX's competition here
RXDX vs GMAB Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, GMAB has a market cap of 15.7B. Regarding current trading prices, RXDX is priced at $199.92, while GMAB trades at $25.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas GMAB's P/E ratio is 19.55. In terms of profitability, RXDX's ROE is -0.31%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, RXDX is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check GMAB's competition here
RXDX vs ASND Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ASND has a market cap of 14.2B. Regarding current trading prices, RXDX is priced at $199.92, while ASND trades at $235.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ASND's P/E ratio is 25.97. In terms of profitability, RXDX's ROE is -0.31%, compared to ASND's ROE of -56.42%. Regarding short-term risk, RXDX is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ASND's competition here
RXDX vs JAZZ Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, JAZZ has a market cap of 14.1B. Regarding current trading prices, RXDX is priced at $199.92, while JAZZ trades at $227.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas JAZZ's P/E ratio is 2042.36. In terms of profitability, RXDX's ROE is -0.31%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, RXDX is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check JAZZ's competition here
RXDX vs BBIO Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, BBIO has a market cap of 13.5B. Regarding current trading prices, RXDX is priced at $199.92, while BBIO trades at $69.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas BBIO's P/E ratio is -18.42. In terms of profitability, RXDX's ROE is -0.31%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, RXDX is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check BBIO's competition here
RXDX vs EXEL Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, EXEL has a market cap of 12.9B. Regarding current trading prices, RXDX is priced at $199.92, while EXEL trades at $51.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas EXEL's P/E ratio is 17.00. In terms of profitability, RXDX's ROE is -0.31%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, RXDX is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check EXEL's competition here
RXDX vs AXSM Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, AXSM has a market cap of 12.8B. Regarding current trading prices, RXDX is priced at $199.92, while AXSM trades at $248.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas AXSM's P/E ratio is -66.45. In terms of profitability, RXDX's ROE is -0.31%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, RXDX is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check AXSM's competition here
RXDX vs KRTX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RXDX is priced at $199.92, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RXDX's ROE is -0.31%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RXDX is less volatile compared to KRTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check KRTX's competition here
RXDX vs IONS Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, IONS has a market cap of 12.2B. Regarding current trading prices, RXDX is priced at $199.92, while IONS trades at $77.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas IONS's P/E ratio is -36.88. In terms of profitability, RXDX's ROE is -0.31%, compared to IONS's ROE of -0.59%. Regarding short-term risk, RXDX is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check IONS's competition here
RXDX vs MDGL Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, RXDX is priced at $199.92, while MDGL trades at $516.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas MDGL's P/E ratio is -37.99. In terms of profitability, RXDX's ROE is -0.31%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, RXDX is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check MDGL's competition here
RXDX vs ARWR Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ARWR has a market cap of 11.6B. Regarding current trading prices, RXDX is priced at $199.92, while ARWR trades at $81.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ARWR's P/E ratio is -36.12. In terms of profitability, RXDX's ROE is -0.31%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, RXDX is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ARWR's competition here
RXDX vs RNAM Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, RXDX is priced at $199.92, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas RNAM's P/E ratio is -17.39. In terms of profitability, RXDX's ROE is -0.31%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, RXDX is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check RNAM's competition here
RXDX vs SMMT Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, SMMT has a market cap of 11.1B. Regarding current trading prices, RXDX is priced at $199.92, while SMMT trades at $14.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas SMMT's P/E ratio is -8.98. In terms of profitability, RXDX's ROE is -0.31%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, RXDX is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check SMMT's competition here
RXDX vs BMRN Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, RXDX is priced at $199.92, while BMRN trades at $56.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas BMRN's P/E ratio is 40.22. In terms of profitability, RXDX's ROE is -0.31%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, RXDX is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check BMRN's competition here
RXDX vs KRYS Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, RXDX is priced at $199.92, while KRYS trades at $345.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas KRYS's P/E ratio is 45.91. In terms of profitability, RXDX's ROE is -0.31%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, RXDX is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check KRYS's competition here
RXDX vs CYTK Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CYTK has a market cap of 9.9B. Regarding current trading prices, RXDX is priced at $199.92, while CYTK trades at $79.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CYTK's P/E ratio is -11.54. In terms of profitability, RXDX's ROE is -0.31%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, RXDX is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CYTK's competition here
RXDX vs NUVL Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, RXDX is priced at $199.92, while NUVL trades at $123.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas NUVL's P/E ratio is -20.37. In terms of profitability, RXDX's ROE is -0.31%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, RXDX is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check NUVL's competition here
RXDX vs IMGN Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RXDX is priced at $199.92, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RXDX's ROE is -0.31%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, RXDX is less volatile compared to IMGN. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check IMGN's competition here
RXDX vs TECH Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, TECH has a market cap of 8.7B. Regarding current trading prices, RXDX is priced at $199.92, while TECH trades at $56.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas TECH's P/E ratio is 79.44. In terms of profitability, RXDX's ROE is -0.31%, compared to TECH's ROE of +0.05%. Regarding short-term risk, RXDX is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check TECH's competition here
RXDX vs CORT Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CORT has a market cap of 8.6B. Regarding current trading prices, RXDX is priced at $199.92, while CORT trades at $81.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CORT's P/E ratio is 227.74. In terms of profitability, RXDX's ROE is -0.31%, compared to CORT's ROE of +0.08%. Regarding short-term risk, RXDX is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CORT's competition here
RXDX vs BPMC Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RXDX is priced at $199.92, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RXDX's ROE is -0.31%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, RXDX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check BPMC's competition here
RXDX vs TGTX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, RXDX is priced at $199.92, while TGTX trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas TGTX's P/E ratio is 19.02. In terms of profitability, RXDX's ROE is -0.31%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, RXDX is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check TGTX's competition here
RXDX vs APGE Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, APGE has a market cap of 8.2B. Regarding current trading prices, RXDX is priced at $199.92, while APGE trades at $132.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas APGE's P/E ratio is -30.61. In terms of profitability, RXDX's ROE is -0.31%, compared to APGE's ROE of -0.33%. Regarding short-term risk, RXDX is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check APGE's competition here
RXDX vs CERE Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RXDX is priced at $199.92, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CERE's P/E ratio is -16.47. In terms of profitability, RXDX's ROE is -0.31%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RXDX is less volatile compared to CERE. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CERE's competition here
RXDX vs HALO Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, HALO has a market cap of 8.2B. Regarding current trading prices, RXDX is priced at $199.92, while HALO trades at $69.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas HALO's P/E ratio is 24.21. In terms of profitability, RXDX's ROE is -0.31%, compared to HALO's ROE of +1.26%. Regarding short-term risk, RXDX is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check HALO's competition here
RXDX vs KYMR Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, KYMR has a market cap of 8.2B. Regarding current trading prices, RXDX is priced at $199.92, while KYMR trades at $96.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas KYMR's P/E ratio is -27.78. In terms of profitability, RXDX's ROE is -0.31%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, RXDX is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check KYMR's competition here
RXDX vs ALKS Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ALKS has a market cap of 7.7B. Regarding current trading prices, RXDX is priced at $199.92, while ALKS trades at $47.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ALKS's P/E ratio is 51.13. In terms of profitability, RXDX's ROE is -0.31%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, RXDX is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ALKS's competition here
RXDX vs IBRX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, IBRX has a market cap of 7.6B. Regarding current trading prices, RXDX is priced at $199.92, while IBRX trades at $7.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas IBRX's P/E ratio is -8.49. In terms of profitability, RXDX's ROE is -0.31%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, RXDX is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check IBRX's competition here
RXDX vs PCVX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, PCVX has a market cap of 7.5B. Regarding current trading prices, RXDX is priced at $199.92, while PCVX trades at $52.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas PCVX's P/E ratio is -7.56. In terms of profitability, RXDX's ROE is -0.31%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, RXDX is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check PCVX's competition here
RXDX vs MTSR Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, RXDX is priced at $199.92, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas MTSR's P/E ratio is -23.58. In terms of profitability, RXDX's ROE is -0.31%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, RXDX is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check MTSR's competition here
RXDX vs PTGX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, PTGX has a market cap of 7.4B. Regarding current trading prices, RXDX is priced at $199.92, while PTGX trades at $119.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas PTGX's P/E ratio is -63.55. In terms of profitability, RXDX's ROE is -0.31%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, RXDX is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check PTGX's competition here
RXDX vs IMVT Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, IMVT has a market cap of 7.3B. Regarding current trading prices, RXDX is priced at $199.92, while IMVT trades at $37.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas IMVT's P/E ratio is -12.76. In terms of profitability, RXDX's ROE is -0.31%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, RXDX is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check IMVT's competition here
RXDX vs RYTM Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, RXDX is priced at $199.92, while RYTM trades at $105.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas RYTM's P/E ratio is -32.39. In terms of profitability, RXDX's ROE is -0.31%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, RXDX is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check RYTM's competition here
RXDX vs MRUS Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, RXDX is priced at $199.92, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas MRUS's P/E ratio is -17.05. In terms of profitability, RXDX's ROE is -0.31%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, RXDX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check MRUS's competition here
RXDX vs ACLX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, RXDX is priced at $199.92, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ACLX's P/E ratio is -28.27. In terms of profitability, RXDX's ROE is -0.31%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, RXDX is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ACLX's competition here
RXDX vs PTCT Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, PTCT has a market cap of 6.7B. Regarding current trading prices, RXDX is priced at $199.92, while PTCT trades at $82.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas PTCT's P/E ratio is -31.87. In terms of profitability, RXDX's ROE is -0.31%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, RXDX is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check PTCT's competition here
RXDX vs LQDA Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, LQDA has a market cap of 6.7B. Regarding current trading prices, RXDX is priced at $199.92, while LQDA trades at $75.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas LQDA's P/E ratio is 444.06. In terms of profitability, RXDX's ROE is -0.31%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, RXDX is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check LQDA's competition here
RXDX vs ABVX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ABVX has a market cap of 6.7B. Regarding current trading prices, RXDX is priced at $199.92, while ABVX trades at $99.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ABVX's P/E ratio is -19.00. In terms of profitability, RXDX's ROE is -0.31%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, RXDX is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ABVX's competition here
RXDX vs RETA Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RXDX is priced at $199.92, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas RETA's P/E ratio is -66.29. In terms of profitability, RXDX's ROE is -0.31%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RXDX is less volatile compared to RETA. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check RETA's competition here
RXDX vs PRAX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, PRAX has a market cap of 6.4B. Regarding current trading prices, RXDX is priced at $199.92, while PRAX trades at $303.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas PRAX's P/E ratio is -22.60. In terms of profitability, RXDX's ROE is -0.31%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, RXDX is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check PRAX's competition here
RXDX vs CNTA Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, RXDX is priced at $199.92, while CNTA trades at $40.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CNTA's P/E ratio is -22.57. In terms of profitability, RXDX's ROE is -0.31%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, RXDX is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CNTA's competition here
RXDX vs COGT Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, COGT has a market cap of 6.1B. Regarding current trading prices, RXDX is priced at $199.92, while COGT trades at $36.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas COGT's P/E ratio is -16.52. In terms of profitability, RXDX's ROE is -0.31%, compared to COGT's ROE of -0.83%. Regarding short-term risk, RXDX is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check COGT's competition here
RXDX vs SYRE Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, SYRE has a market cap of 6.1B. Regarding current trading prices, RXDX is priced at $199.92, while SYRE trades at $98.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas SYRE's P/E ratio is -47.32. In terms of profitability, RXDX's ROE is -0.31%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, RXDX is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check SYRE's competition here
RXDX vs BLTE Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, RXDX is priced at $199.92, while BLTE trades at $146.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas BLTE's P/E ratio is -57.90. In terms of profitability, RXDX's ROE is -0.31%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, RXDX is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check BLTE's competition here
RXDX vs SRRK Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, RXDX is priced at $199.92, while SRRK trades at $51.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas SRRK's P/E ratio is -14.22. In terms of profitability, RXDX's ROE is -0.31%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, RXDX is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check SRRK's competition here
RXDX vs CGON Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CGON has a market cap of 5.8B. Regarding current trading prices, RXDX is priced at $199.92, while CGON trades at $65.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CGON's P/E ratio is -28.31. In terms of profitability, RXDX's ROE is -0.31%, compared to CGON's ROE of -0.23%. Regarding short-term risk, RXDX is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CGON's competition here
RXDX vs CDTX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, RXDX is priced at $199.92, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CDTX's P/E ratio is -19.77. In terms of profitability, RXDX's ROE is -0.31%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, RXDX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check CDTX's competition here
RXDX vs ABCM Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RXDX is priced at $199.92, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RXDX's ROE is -0.31%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RXDX is less volatile compared to ABCM. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ABCM's competition here
RXDX vs ISEE Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RXDX is priced at $199.92, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RXDX's ROE is -0.31%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RXDX is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ISEE's competition here
RXDX vs LEGN Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, LEGN has a market cap of 5.4B. Regarding current trading prices, RXDX is priced at $199.92, while LEGN trades at $29.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas LEGN's P/E ratio is -21.26. In terms of profitability, RXDX's ROE is -0.31%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, RXDX is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check LEGN's competition here
RXDX vs MIRM Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, MIRM has a market cap of 5.4B. Regarding current trading prices, RXDX is priced at $199.92, while MIRM trades at $108.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas MIRM's P/E ratio is -7.91. In terms of profitability, RXDX's ROE is -0.31%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, RXDX is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check MIRM's competition here
RXDX vs FBIOX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, RXDX is priced at $199.92, while FBIOX trades at $26.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas FBIOX's P/E ratio is N/A. In terms of profitability, RXDX's ROE is -0.31%, compared to FBIOX's ROE of N/A. Regarding short-term risk, RXDX is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check FBIOX's competition here
RXDX vs LGND Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, LGND has a market cap of 5.3B. Regarding current trading prices, RXDX is priced at $199.92, while LGND trades at $272.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas LGND's P/E ratio is 34.05. In terms of profitability, RXDX's ROE is -0.31%, compared to LGND's ROE of +0.16%. Regarding short-term risk, RXDX is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check LGND's competition here
RXDX vs APLS Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, RXDX is priced at $199.92, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas APLS's P/E ratio is 38.35. In terms of profitability, RXDX's ROE is -0.31%, compared to APLS's ROE of +0.40%. Regarding short-term risk, RXDX is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check APLS's competition here
RXDX vs CRSP Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, RXDX is priced at $199.92, while CRSP trades at $54.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CRSP's P/E ratio is -8.81. In terms of profitability, RXDX's ROE is -0.31%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, RXDX is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CRSP's competition here
RXDX vs TVTX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, TVTX has a market cap of 5.1B. Regarding current trading prices, RXDX is priced at $199.92, while TVTX trades at $55.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas TVTX's P/E ratio is -110.22. In terms of profitability, RXDX's ROE is -0.31%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, RXDX is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check TVTX's competition here
RXDX vs CAI Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CAI has a market cap of 4.9B. Regarding current trading prices, RXDX is priced at $199.92, while CAI trades at $17.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CAI's P/E ratio is -6.27. In terms of profitability, RXDX's ROE is -0.31%, compared to CAI's ROE of +0.06%. Regarding short-term risk, RXDX is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CAI's competition here
RXDX vs TERN Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, RXDX is priced at $199.92, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas TERN's P/E ratio is -51.41. In terms of profitability, RXDX's ROE is -0.31%, compared to TERN's ROE of -0.20%. Regarding short-term risk, RXDX is less volatile compared to TERN. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check TERN's competition here
RXDX vs ERAS Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ERAS has a market cap of 4.7B. Regarding current trading prices, RXDX is priced at $199.92, while ERAS trades at $15.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ERAS's P/E ratio is -16.22. In terms of profitability, RXDX's ROE is -0.31%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, RXDX is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ERAS's competition here
RXDX vs FOLD Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, RXDX is priced at $199.92, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas FOLD's P/E ratio is -161.00. In terms of profitability, RXDX's ROE is -0.31%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, RXDX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check FOLD's competition here
RXDX vs AKRO Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, RXDX is priced at $199.92, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas AKRO's P/E ratio is -14.57. In terms of profitability, RXDX's ROE is -0.31%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, RXDX is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check AKRO's competition here
RXDX vs ALPN Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RXDX is priced at $199.92, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RXDX's ROE is -0.31%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RXDX is less volatile compared to ALPN. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ALPN's competition here
RXDX vs CELC Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CELC has a market cap of 4.4B. Regarding current trading prices, RXDX is priced at $199.92, while CELC trades at $92.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CELC's P/E ratio is -23.06. In terms of profitability, RXDX's ROE is -0.31%, compared to CELC's ROE of -2.45%. Regarding short-term risk, RXDX is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CELC's competition here
RXDX vs XENE Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, XENE has a market cap of 4.3B. Regarding current trading prices, RXDX is priced at $199.92, while XENE trades at $54.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas XENE's P/E ratio is -11.66. In terms of profitability, RXDX's ROE is -0.31%, compared to XENE's ROE of -0.49%. Regarding short-term risk, RXDX is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check XENE's competition here
RXDX vs KNSA Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, KNSA has a market cap of 4.3B. Regarding current trading prices, RXDX is priced at $199.92, while KNSA trades at $58.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas KNSA's P/E ratio is 62.78. In terms of profitability, RXDX's ROE is -0.31%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, RXDX is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check KNSA's competition here
RXDX vs MANE Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, RXDX is priced at $199.92, while MANE trades at $105.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas MANE's P/E ratio is -38.78. In terms of profitability, RXDX's ROE is -0.31%, compared to MANE's ROE of -0.95%. Regarding short-term risk, RXDX is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check MANE's competition here
RXDX vs VCYT Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, VCYT has a market cap of 4.2B. Regarding current trading prices, RXDX is priced at $199.92, while VCYT trades at $53.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas VCYT's P/E ratio is 49.25. In terms of profitability, RXDX's ROE is -0.31%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, RXDX is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check VCYT's competition here
RXDX vs OPT Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RXDX is priced at $199.92, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas OPT's P/E ratio is -1.52. In terms of profitability, RXDX's ROE is -0.31%, compared to OPT's ROE of +1.09%. Regarding short-term risk, RXDX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check OPT's competition here
RXDX vs MRTX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RXDX is priced at $199.92, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RXDX's ROE is -0.31%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RXDX is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check MRTX's competition here
RXDX vs DFTX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, DFTX has a market cap of 4B. Regarding current trading prices, RXDX is priced at $199.92, while DFTX trades at $38.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas DFTX's P/E ratio is N/A. In terms of profitability, RXDX's ROE is -0.31%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, RXDX is less volatile compared to DFTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check DFTX's competition here
RXDX vs EWTX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, EWTX has a market cap of 3.9B. Regarding current trading prices, RXDX is priced at $199.92, while EWTX trades at $38.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas EWTX's P/E ratio is -21.99. In terms of profitability, RXDX's ROE is -0.31%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, RXDX is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check EWTX's competition here
RXDX vs CPRX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, RXDX is priced at $199.92, while CPRX trades at $31.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CPRX's P/E ratio is 18.14. In terms of profitability, RXDX's ROE is -0.31%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, RXDX is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CPRX's competition here
RXDX vs DNLI Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, DNLI has a market cap of 3.8B. Regarding current trading prices, RXDX is priced at $199.92, while DNLI trades at $25.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas DNLI's P/E ratio is -8.35. In terms of profitability, RXDX's ROE is -0.31%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, RXDX is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check DNLI's competition here
RXDX vs ACAD Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, RXDX is priced at $199.92, while ACAD trades at $22.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ACAD's P/E ratio is 10.00. In terms of profitability, RXDX's ROE is -0.31%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, RXDX is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ACAD's competition here
RXDX vs VKTX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, RXDX is priced at $199.92, while VKTX trades at $35.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas VKTX's P/E ratio is -7.80. In terms of profitability, RXDX's ROE is -0.31%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, RXDX is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check VKTX's competition here
RXDX vs RYZB Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RXDX is priced at $199.92, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RXDX's ROE is -0.31%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RXDX is less volatile compared to RYZB. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check RYZB's competition here
RXDX vs CRNX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CRNX has a market cap of 3.7B. Regarding current trading prices, RXDX is priced at $199.92, while CRNX trades at $36.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CRNX's P/E ratio is -6.88. In terms of profitability, RXDX's ROE is -0.31%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, RXDX is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CRNX's competition here
RXDX vs CBAY Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RXDX is priced at $199.92, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RXDX's ROE is -0.31%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RXDX is less volatile compared to CBAY. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CBAY's competition here
RXDX vs BEAM Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, BEAM has a market cap of 3.7B. Regarding current trading prices, RXDX is priced at $199.92, while BEAM trades at $33.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas BEAM's P/E ratio is -72.51. In terms of profitability, RXDX's ROE is -0.31%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, RXDX is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check BEAM's competition here
RXDX vs DNTH Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, DNTH has a market cap of 3.6B. Regarding current trading prices, RXDX is priced at $199.92, while DNTH trades at $87.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas DNTH's P/E ratio is -20.65. In terms of profitability, RXDX's ROE is -0.31%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, RXDX is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check DNTH's competition here
RXDX vs NAMS Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, NAMS has a market cap of 3.6B. Regarding current trading prices, RXDX is priced at $199.92, while NAMS trades at $30.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas NAMS's P/E ratio is -17.31. In terms of profitability, RXDX's ROE is -0.31%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, RXDX is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check NAMS's competition here
RXDX vs TNGX Comparison June 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, TNGX has a market cap of 3.5B. Regarding current trading prices, RXDX is priced at $199.92, while TNGX trades at $29.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas TNGX's P/E ratio is -34.34. In terms of profitability, RXDX's ROE is -0.31%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, RXDX is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check TNGX's competition here